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Human DNA adduct formation (covalent modification of DNA with chemical carcinogens) is a
promising biomarker for elucidating the molecular epidemiology of cancer. Classes of compounds
for which human DNA adducts have been observed include polycyclic aromatic hydrocarbons
(PAHs), nitrosamines, mycotoxins, aromatic amines, heterocyclic amines, ultraviolet light, and
alkylating cancer chemotherapeutic agents. Most human DNA adduct exposure monitoring
has been performed with either 32P-postlabeling or immunoassays, neither of which is able to
chemically characterize specific DNA adducts. Recently developed combinations of methods with
chemical and physical end points have allowed identification of specific adducts in human tissues.
Studies are presented that demonstrate that high ambient levels of benzo[alpyrene are associated
with high levels of DNA adducts in human blood cell DNA and that the same DNA adduct levels
drop when the ambient PAH levels decrease significantly. DNA adduct dosimetry, which has
been achieved with some dietary carcinogens and cancer chemotherapeutic agents, is described,
as well as studies correlating DNA adducts with other biomarkers. It is likely that some toxic,
noncarcinogenic compounds may have genotoxic effects, including oxidative damage, and
that adverse health outcomes other than cancer may be correlated with DNA adduct formation.
The studies presented here may serve as useful prototypes for exploration of other toxicological
end points. Environ Health Perspect 104(Suppl 5):883-893 (1996)
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enzyme-linked immunosorbent assay, 32P-postlabeling, fluorescence spectroscopy, gas
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Introduction
A large body of evidence in experimental promising biomarker for elucidating the
systems suggests that DNA adduct forma- molecular epidemiology of cancer (3,4).
tion is necessary, but not sufficient, for Classes of compounds for which human
tumorigenesis caused by genotoxic chemi- DNA adducts have been measured include
cal carcinogens (1,2). Thus, human DNA polycyclic aromatic hydrocarbons (PAHs),
adduct formation (covalent modification of nitrosamines, mycotoxins, aromatic amines,
DNA with chemical carcinogens) is a heterocyclic amines, ultraviolet (UV) light
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and alkylating cancer chemotherapeutic
agents. Human exposures that result in
DNA adduct formation are listed in Tables
1 and 2, and some chemical structures of
DNA adducts are shown in Figure 1. It is
generally considered that DNA adduct for-
mation represents biologically effective
dose, or dose reaching a target tissue, and it
is assumed that DNA adduct measure-
ments have the potential to become inte-
gral components of the risk-assessment
process. At the present time many techno-
logical approaches have sufficient sensitiv-
ity to measure human DNA adducts and
are being used widely for exposure assess-
ment. The advancement of the field to
DNA adduct-based cancer risk assessment
requires the implementation of adduct
measurements within epidemiologically
sound study designs, an area that is still in
the early stages of development. It is also
possible that toxic, but noncarcinogenic,
compounds form DNA adducts and may
have other adverse health outcomes for
which DNA adduct formation may there-
fore be an appropriate biomarker.
Methods that have been used for
sensitive detection of carcinogen-DNA
adducts in humans include immunoassays
(5), immunohistochemistry (6,7), 32p_
postlabeling, (8,9), fluorescence and
phosphorescence spectroscopy (10), gas
chromatography-mass spectrometry
(GC-MS) (11), atomic absorbance spec-
trometry (AAS) (12,13) and electrochemi-
cal conductance (ECC) (14). Typically,
the techniques that are used without
preparative procedures are not absolutely
quantitative or able to chemically charac-
terize a specific adduct, but they are highly
effective screening tools. Recent advances
combining preparative methods [immuno-
affinity chromatography (IAC), high per-
formance liquid chromatography (HPLC)
or other chromatography] with immunoas-
says, 32P-postlabeling, synchronous fluores-
cence spectrometry (SFS), and GC-MS
have allowed identification and quantita-
tion of specific DNA adducts in human
tissues potentially resulting in more precise
exposure documentation.
This paper is an overview of method-
ologies and their application in exposure
biomonitoring, focusing on human blood
cell PAH-DNA adduct measurements
obtained concomitantly with ambient
PAH monitoring. DNA adduct dosimetry
and correlation of DNA adducts with
other biomarkers are considered.
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Table 1. Sensitivities and exposures measured for human DNA adduct detection using antisera specific for DNA
adducts or modified DNA samples.
Assay Adducts detected per 108 nucleotides Exposure Reference
Immunoassay > 1 Aflatoxins (27-29)
4-Aminobiphenyl (30,31,130)
Cisplatin and carboplatin (38,85,116,131)
Coal tar(medicinal) (41)
Dacarbazine (40)
8-Methoxypsoralen (42)
Oxidative damage (43)
PAHs (35-37,108,132)
Procarbazinea (39,117)
Ultraviolet light (44)
Immunohistochemistry 2 100 Aflatoxins (7)
Cisplatin (6,45)
8-Methoxypsoralen (46,47)
Ultraviolet light (48)
aCompetitive repair assay, analogous to immunoassay.
Table 2. Sensitivities and exposures measured for human DNA adduct detection by 32P-postlabeling and other
assays.
Assay Adducts detected per 108 nucleotides Exposure Reference
32p-Postlabeling 0.1 Coal tar(medicinal) (133)
Mitomycin C (134)
MOCA (135)
Ochratoxin A (136)
PAHs (9,55,105,109,
137-139)
Styrene (140-142)
Tobacco (143-145)
Unknown (36,146-149)
Luminescence 10-100 Aflatoxins (63,150)
spectroscopy B[a]P (61,67,151)
PAH (occupational) (65,66)
GC-MS 0.3-1 4-Aminobiphenyl (83)
N-Nitrosamines (11,73,77,78,80)
NNK (tobacco) (81)
PhIP(diet) (84)
Malondialdehyde (endogenous) (152)
Atomic absoprtion 100 Cisplatin and carboplatin (86,153)
spectrometry
Electrochemical 0o.i- a Oxidative damage (93,94)
conductance
8Picomole per milliliter of urine.
Major Methodsfor DNA
Adduct Determination
in Human Tissues and
Examples of Human
Exposure Monitoring
Immunoassays
Antisera elicited against DNA adducts and
carcinogen-modified DNA samples (15-17)
have been widely used to quantify and
localize xenobiotic-induced DNA damage
(18-21) and to measure DNA adduct for-
mation in human tissues (22,23). Com-
petitive radioimmunoassays (RIAs) and
enzyme-linked immunosorbent assays
(ELISAs), able to detect human DNA
damage with sensitivity in the range ofone
adduct in 108 unmodified nucleotides,
have been established with these antisera.
Immunoassays are reliable, inexpensive,
and allow for the analysis ofmore than 20
samples per day. Disadvantages include the
requirement for relatively large amounts of
DNA (200 pg) and a lack of absolute
specificity because of antibody cross-reac-
tivity. Cross-reactivity with unmodified
DNA, unmodified nucleotides, or carcino-
gen alone rarely occurs (24), but there may
be recognition ofother adducts ofthe same
carcinogen or adducts ofother chemically
related compounds (25). Therefore, unless
prior separation of adducts is used, the
values obtained for human samples may
reflect measurement of multiple, chemi-
cally similar DNA adducts. In addition to
use with quantitative immunoassays, anti-
carcinogen DNA adduct antisera have been
used for immunohistochemical staining of
human tissues (21,23,26). In general,
immunohistochemistry is less sensitive
than ELISA, but the approach may be rele-
vant for identification of susceptible cell
types in complex tissues.
Xenobiotic exposures that have been
examined by immunoassay in samples from
human subjects (Table 1) include afla-
toxins (27-29), 4-aminobiphenyl (30,31),
N-nitrosamines (32-34), benzo[a]pyrene
(B[a]P), and other PAHs (35-37). In addi-
tion, medicinal exposures, including cis-
diamminedichloroplatinum (II) (cisplatin)
(38), procarbazine (39), dacarbazine (40),
coal tar (41), and 8-methoxypsoralen (42)
have been determined in DNA ofpatients.
Oxidative DNA damage (43) and UV
light photoproducts (44) have also been
measured by immunoassay. Immuno-
histochemistry to localize DNA adducts in
human tissues (Table 1) has been used for
aflatoxins (7), cisplatin (6,45), 8-methoxy-
psoralen (46,47), and UV light (48).
32p-posdabeling
The 32P-postiabeling technique is widely
used for human DNA adduct detection
(9,20,23), largely because of its high sensi-
tivity (routinely one adduct in 109 nucleo-
tides) and application to small quantities of
DNA (2-10 pg). The method is based on
the radiolabeling of adducts with high
specific activity 32p from y32P-ATP by T4
polynucleotide kinase. DNA isolated from
a tissue of interest is digested to 3'-mono-
phosphates and phosphorylated to form 5'-
32P-3'-bisphosphates. Adducts in the
labeled mixture are separated by thin layer
chromatography (TLC) in multiple (most
often four) directions. Relative quantita-
tion has been approached by scraping
materials from the TLC plates and subject-
ing them to radiochemical analysis; how-
ever, recent development of a sensitive
radiomatic apparatus for chromatogram
scanning facilitates the quantitation and
provides a measure ofprotection for labo-
ratory personnel. Advantages and disadvan-
tages ofthis method have been discussed in
detail elsewhere (23,49).
Individuals receiving many different
types of potentially genotoxic exposures
have been demonstrated to have potential
adduct spots by 32P-postlabeling (Table 2),
and in the absence of other information
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Figure 1. Structures of representative DNA adducts. (A) (7R)-N2-{1O-[r-7, t-8, t-9-trihydroxy-7,8,9,1
benzo[a]pyrene]yI}-deoxyguanosine; (B) N-deoxyguanosin-(8-yI)-2-acetylaminofluorene; (C) N-deoxygu
2-aminofluorene; (0) N2-(2'-dG-8-yI)-2-amino-1 -methyl-6-phenylimidazo[4,5-b]pyridine;(
B1-N7-deoxyguanosine; (F) 05-methyldeoxyguanosine; (G) N7-methyldeoxyguanosine; (H) 8-hydroxydeo
these are termed "aromatic adducts." The
chemical identification ofsuch adducts has
rarely been achieved, but recent sophisti-
cated modifications to the basic methodol-
ogy have allowed tentative identification of
some specific adducts (30,50,51). Overall,
correlations of adduct levels with docu-
mented human exposure appear to be good
(52-56), but the quantitative data should
be interpreted with caution because the
adducts are unidentified and the efficiency
of phosphorylation is often unknown and
uncontrolled (51,57-60).
Luminescence and
Phosphorescence Spectroscopy
Luminescence spectroscopy is possible only
with carcinogens having intrinsic fluores-
cence, such as PAHs and aflatoxins. In
SFS, both the excitation and emission
monochromators are driven simultaneously
at a distance equal to the Stoke's shift so
that a fluorescence signal is observed when
the last excitation maximum and first emis-
sion maxima are met. This approach sim-
plifies the spectrum and allows for the
generation of more complete fluorescence
excitation-emission matrices (61-63).
Conventional SFS detection of (7R)-N2-
110-[r-7,t-8,t-9- trihydroxy-7,8,9,10-
tetrahydrobenzo[a]pyrene]yl}-deoxyguanos
ine (BPdG) in human tissues rec
hydrolysis (0.1 N HCI, 90°C, 3
DNA and isolation ofthe B[a]P i
r-7,t-8,t-9, c- I0-tetrahydroxy-
tetrahydrobenzo[a]pyrene, (BP-
tetrol). A detection limit of one
106 to 107 unmodified nucleotide
achieved for 100 pg ofDNA (64-
A recently developed approac
the use of analytical solid mat
phorescence spectroscopy to d
7,10/8,9-tetrol. The method us
matrix composed ofhydrophobic
trins to adsorb PAH residues fo
laser excitation (67), and tht
detection is 20 to 50 times li
conventional SFS.
The major limitations to t
fluorescence spectroscopy for the
ofcarcinogen DNA damage in h
lack of prior knowledge of addi
istry, a requirement that the a
fluorescent, and a requirement
tively large quantities of sam
(100-1000 pg). After the initial
equipment, assays can be p
rapidly and inexpensively. To d;
2), fluorescence studies have been
to detection of DNA adducts co
pyrene fluorophore (49,68), de
exfoliated aflatoxin adducts in u
0' 0 and N7-methyl-deoxyguanosine (N7me-
IR dG) and 06methyl-deoxyguanosine
</ (06me-dG) adducts in liver in a case of
acute poisoning (70).
OCH3 Gas Chromatography-Mass
Spectrometry
Gas chromatography-mass spectrometry
(49,71) is highly specific and has had
widespread application in measurement of
both carcinogen-protein adducts and car-
,CH3 cinogen-DNA adducts (72-76). Mass
s<Ns spectrometry requires derivitization ofthe
compound ofinterest to increase mass and
N volatility; vaporization ofthe sample; ion-
RlsosE ization, which can be achieved in a number
d RIBOSE of ways (electron impact, fast atom bom-
bardment, chemical ionization, and laser
desorption); collimation of the charged
particles; and acceleration into the mass
analyzer. The spectrum of ions detected
comprises the molecular ion plus the frag-
ment ions including the base peak. The
base peak, the most intense signal, is most
0-tetrahydro- commonly used for quantitative sample
ianosin-(8-y1)- analysis by single-ion monitoring when the
[E) aflatoxin mass spectrum ofa compound ofinterest is
xyguanosine. already known.
Methods using GC-MS have been
developed for several different exposures
luires acid (Table 2). Alkyl purine adducts in human
hr) ofthe urine have been the most extensively stud-
residues as ied (11,72,73,77-80). These investigations
7,8,9,10- have examined the exfoliation of adducts
-7,10/8,9- by seeking the presence of N7me-dG,
adduct in N7et-dG, N7-hydroxethyldeoxygua-
s has been nosine (N7-OHet-dG), 3-methyladenine
-66). (3me-Ade), 3-ethyladenine (3et-Ade), 3-
-h involves hydroxyethyladenine (3OHet-Ade), and 3-
trix phos- benzyladenine (3bz-Ade) in human urine.
Ietect BP- Investigations using single-ion monitoring
ses a solid GC-MS have been extended to the mea-
cyclodex- surement of4-(N-nitrosomethylamino)-1-
ollowed by (3-pyridyl)-1-butanone (NNK) adducts in
e limit of human lung and tracheal DNA ofsmokers
wer than and nonsmokers (81). In addition, the
presence of BPdG has been demonstrated
the use of in placental tissues of smokers and non-
detection smokers (82). Samples of human urinary
iumans are bladder and lung DNA, digested and sub-
uct chem- jected to negative ion GC-MS, were shown
adduct be to contain N-deoxyguanosin-(8-yl)-4-
t for rela- aminobiphenyl (dG-C8-4-ABP) at levels
ple DNA that compared well with 32P-postlabeling
cost ofthe analysis of the same samples using appro-
erformed priate standards (83). Similarly, the C-8
ate (Table DNA adduct of the heterocyclic amine
i restricted 2-amino-1-methyl-6-phenylimidazo-
ntaining a [4,5-b]pyridine (PhIP) was observed by
tection of GC-MS after hydrolysis from human
rine (69), colon (84).
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AtomicAbsorbance Spectrometry
Atomic absorbance spectrometry is an
analytical method for determining ele-
ments based on the absorbance ofradiation
by free atoms released by high-temperature
combustion. It is most valuable in the
detection of metal ions and has been suc-
cessfully applied, for human dosimetry, in
the monitoring of DNA from cancer
patients treated with the platinum drugs,
cisplatin and diamminecyclobutane-dicar-
boxylatoplatinum (II) (carboplatin) (Table
2). These drugs have been shown by AAS
(12) and other methods to bind covalently
to DNA (45,85-87). For measurement of
platinum bound to DNA in tissues of
human cancer patients, unknown samples
are quantified by comparison to a standard
curve, and sufficient sensitivity is only
obtained using an AAS with Zeeman back-
ground correction (86,88).
Electochemical Conductance
Electrochemical conductance requires the
application ofavoltage across two electrodes
that are immersed in an electrolytic solu-
tion. An electric current flows, allowing the
measurement of electrical conductance,
which is proportional to the analyte concen-
tration (89). This technique has the advan-
tage ofspecificity because it can be directly
applied to individual HPLC fractions (14).
However, factors related to the chromato-
graphic conditions (gradient elution, tem-
perature, and pressure) may cause problems
with detector performance (90,91).
Electrochemical conductance has been
used to monitor oxidative damage in DNA
(Table 2). This use ofthe method is com-
plicated by the fact that oxidation of DNA
may occur during the extraction procedure
(92); however, 8-hydroxydeoxyguanosine
(80H-dG) is detectable, whereas unmodi-
fied deoxyguanosine is not. The approach is
sufficiently specific and sensitive for human
biomonitoring, but investigations so far
have been limited to determining 80H-dG
in urine, peripheral white blood cells, or
bronchial alveolar macrophages (93,94).
Combinations ofMethods
The most frequently applied detection
methods, immunoassays, 32P-postlabeling,
and fluorescence spectroscopy, used in the
absence of micropreparative techniques,
provide a broad screen and indicate expo-
sure. However, recently devised combina-
tions of methods produce more specific
and readily comprehensible data. Such
approaches are necessarily more labor
intensive, time consuming, expensive, and
demanding when applied to large numbers
of specimens, but the information they
provide is invaluable for human exposure
assessment.
Most combinations of methods to
improve the specificity of DNA adduct
detection use either conventional chro-
matographic separation or immunoaffinity
chromatography as a first step. When a
human DNA sample is digested and sub-
jected to HPLC, even though the adducts
cannot be observed by conventional moni-
toring, the fractions known to contain
specific adducts can be analyzed by immu-
noassay, 32P-postlabeling, or GC-MS. For
example, the sensitivity and specificity of
ELISAs for human DNA adduct monitor-
ing have been enhanced by combination
with prior HPLC. This approach has been
applied to human gastric mucosa (32) and
liver samples (33) using antisera specific
for alkyl-modified nucleosides. Chromato-
graphic separation by HPLC has also been
combined with 32P-postlabeling; a recent
review (59) covers the subject. A highly
successful line ofexperimentation has com-
bined two chromatographic steps with 32p_
postlabeling to detect specific o6- and
N7-alkyl-dG adducts in human lung and
lymphocytes (51,57,95). The development
of this method has facilitated the use of
internal and cochromatography standards.
In an another approach, Stillwell et al. (79)
employed two chromatographic steps prior
to the GC-MS determination of 3me-dA
and 7me-dG adducts in the urine ofsmok-
ers. Finally, in a novel set ofexperiments,
HPLC was used as the first step ofa proce-
dure combining 32P-postlabeling with
immunoprecipitation (termed PREPI) for
the detection of06me-dG, 04me-dG, and
04et-dG in human liver and leukocyte
DNA samples (50).
Immunoaffinity chromatography pro-
vides a valuable purification step that has
been widely used to improve the specificity
of other methods. Antibodies elicited
against DNA adducts or carcinogen-
modified DNA samples can be covalently
bound to a matrix and the resulting mater-
ial used in columns that bind and elute
specific adducts in a DNA digest. Because
most antisera have cross-reactivity for fami-
lies of structurally similar DNA adducts,
IAC concentrates structurally similar DNA
adducts (96-98). Further separation of
adducts by HPLC is frequently required
before specific adduct determination
is possible.
For PAH exposure, IAC and HPLC of
human lung and placenta have been
combined with different end points,
including SFS (82,98,99), GC-MS (82),
and 32P-postlabeling (99,100), to provide
evidence of BPdG formation. Using this
methodology, it is possible to detect one
BPdG adduct in 108 nucleotides.
Immunoaffinity chromatography and
GC-MS have been combined to detect
exfoliated 3-alkyl-adenines in human urine
(11,80). Recently, Bianchini et al. (101)
reported the combination of IAC, HPLC,
and ECC to measure N7me-dG in human
pancreas. Aflatoxin exposure dosimetry has
been accomplished by combining IAC
with HPLC and UV absorbance (A362) to
detect adducts in human urine and tissues
(28,102,103). In other studies IAC has
been combined with 32P-postlabeling and
TLC to detect 06 me-dG (104).
Human DNA Adduct
Formation as an Exposure
Dosimeter
Comparison ofAmbientB[a]P Levels
with DNAAdductFormation
A number ofinvestigatiors have attempted
to monitor ambient air for B[a]P and other
PAHs while simultaneously measuring
blood cell DNA adducts in occupationally
or environmentally exposed individuals.
Studies focused only on smoking have been
excluded here because the dosimetry is nec-
essarily crude, and PAH-DNA adduct
levels in blood-cell DNA are not consis-
tently higher in smokers. In fact, the results
suggest that smoking is only one of many
factors that contribute to adduct formation
in blood cell DNA. This analysis focuses
on adduct measurements in human blood-
cell DNA because human tissue biopsies
are not practical for routine analysis.
A summary of investigations in which
ambient B[a]P levels were compared to
PAH-DNA adduct analyses in human
blood cells is shown in Table 3. Overall,
the data suggest that increased ambient
pollution levels (using B[a]P as an indica-
tor) are associated with higher levels of
blood-cell PAH-DNA adducts, and that
measures taken to remove B[a]P (and
presumably other PAHs) from the environ-
ment yield dividends in terms of lowered
biologically effective dose. Two studies in a
population of Finnish foundry workers,
performed several years apart, indicate
that decreasing the B[a]P levels from
12-200 ng/m3 to < 5-60 ng/m3 signifi-
cantly reduced the PAH-DNA adduct
levels measured by the anti-BPdG-
DNA-ELISA (37,41). In addition, lower
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Table 3. Human white blood-cell DNA adduct levels (adducts/108 nucleotides) as a function of ambient benzo[alpyrene (ng/m3) levels.
Cohort <1 ng/m3 <5 ng/m3 5-12 ng/m3 12-60 ng/m3 50-50,000 ng/m3 Assay Reference
Finnish foundry 2.2a 8.0 21.0, 50.0 ELISA (37)
Finnish foundry 5.2 6.1 9.6 ELISA (41)
Dutch coke ovens 2.8a 5.2 ELISA (109)
Polish coke ovens 8.2 24.5 32P-Postlabeling (110)
2.3 15.3 ELISA
Silesia, Poland 1.3(summer)b 6.4(winter)b 32P-Postlabeling (107)
U.S. Army soldiers 1.6 (Kuwait) 4.0(Germany) DELFIA (106)
1.7 (Kuwait) 3.0 (Germany) 32P-Postlabeling
Chinese women 9.2(methane)c 3.3 (smokycoal)c ELISA (108)
For comparison, ambient B[a]P levels from cigarette smoking are 2.8 to 760 ng/m3 (154). 8Controls. Ambient monitoring was typically not conducted for individuals serving as
controls. bONAadduct values are for lymphocytes only. COfthe methane controls, 4/16 (25%)were positive; forsamples from coal smoke, 17/30(57%) were positive.
PAH-DNA adduct levels were measured
in the same workers after time spent on
vacation (105).
In a study of U.S. Army soldiers, mili-
tary personnel were monitored before, dur-
ing, and after a tour of duty in Kuwait
(106). It was expected that higher expo-
sure to PAHs would result from oil-well
fires burning at that time. However, the
DNA adduct and air sampling data indi-
cate that these soldiers went from a clean
environment in Kuwait in August to signi-
ficantly higher pollution levels in Germany
in October, and DNA adducts, assayed by
both BPdG-DNA dissociation-enhanced
lanhtanide fluoroimmunoassay and 32p-
postlabeling, increased significantly (106).
Another example ofpollution modula-
tion and concomitant reduction in DNA
adduct levels occurred in the Silesian
region of Poland in the summertime; the
air was approximately 5-fold cleaner than
in the winter, and the levels ofadducts in
lymphocytes was approximately 5-fold
lower (107). One should note, however,
that the adduct dosimetry shown here to
reflect ambient PAH levels is not consis-
tent with the much higher levels ofambi-
ent B[a]P and the disproportionately low
adduct levels observed in other studies
(Table 3).
Ofall the studies summarized in Table
3, the highest reported ambient B[a]P
levels were 2283 ng/m3 for Chinese women
breathing coal smoke (108), 7800 ng/m3
for Dutch coke oven workers (109), and
50,000 ng/m3 for Polish coke oven work-
ers (110). Ofthese, neither Dutch coke
oven workers nor Chinese women had pro-
portionately higher DNA adduct levels.
The Chinese women, who have a high lung
cancer risk, were exposed to coal smoke
while cooking meals (108), but the Dutch
workers experienced 100 to 7800 ng/m3
during a 40-hr week (109). Therefore,
in analyzing these data, a number of
confounding factors must be recognized.
The use of ambient B[a]P measurements
provide an indicator ofthe pollution levels,
but the actual hydrocarbon components
vary and are not always measured. The
BPdG-DNA immunoassays used actually
measure BPdG as well as a broad spectrum
of PAH-DNA adducts, since the anti-
serum used in many studies (96,111,112)
recognizes multiple PAH-DNA adducts
(98). In addition, cohorts are grouped
according to the highest exposure docu-
mented, but the range ofexposures for one
job at one work site can vary considerably.
Overall, the data suggest that DNA adduct
levels vary with pollution, and that B[a]P
may not be the compound responsible for
producing the majority of PAH-DNA
adducts observed by immunoassay and
32P-postlabeling in human blood cells.
DNAAdductDosimetry
As discussed above, because much of the
available human DNA adduct dosimetry
for occupational and environmental expo-
sures depends on ambient biomonitoring,
precise dose-response relationships have
not been possible. However, in some
studies with dietary carcinogen exposure
and others involving DNA-damaging
cancer chemotherapeutic agents, dosimetry
has been demonstrated.
In one study involving California fire-
fighters (113), blood samples were taken
before the summer firefighting season
began and 8 weeks later. PAH-DNA
adducts were measured by BPdG-DNA
ELISA and did not correlate with the
extent offirefighting. Comparison ofques-
tionnaire results with DNA adduct values
showed that individuals (n= 19) consum-
ing charbroiled food one to two times in
the previous week had a mean PAH-DNA
adduct value of 1.6 adducts in 108 nucleo-
tides. Twenty-three individuals who
reported consumption ofthese foods three
to five times in the previous week and five
individuals reporting consumption more
than five times in the previous week
had mean adduct values of 3.0 and 6.7
adducts/108 nucleotides, respectively. The
largest single source responsible for PAH-
DNA adduct formation was consumption
ofcharbroiled food.
For dosimetry ofaflatoxin exposure, 42
individuals in the Guangxi region ofChina
were studied (103). Samples of the food
consumed were assayed for aflatoxin con-
tent, which was correlated with the urinary
excretion ofaflatoxin-N7-guanine (AFB1-
N7-G) by both males and females. Immu-
noaffinity chromatography and HPLC were
used to isolate metabolites and adducts from
urine (28,114) and fluorescence emission
spectra were used to identify theAFB1-N7-
G. The dosimetry data showed an excellent
correlation between dietary aflatoxin intake
and urinaryadduct excretion (69).
Cancer chemotherapy has presented
unique opportunities to demonstrate DNA
adduct dosimetry because the doses ofdrug
are precisely known. Analysis ofblood-cell
DNA from 77 previously untreated ovarian
and testicular cancer patients receiving
platinum drug-based therapy showed
strong DNA adduct dosimetry in patients
with measurable DNA adduct levels
(115,116). In studies with procarbazine
and dacarbazine, which were used to treat
patients with Hodgkin's lymphoma, an
excellent correlation was shown between
cumulative drug dose and blood-cell DNA
levels ofthe O6me-dG adduct (39,117). In
general, the presence ofhigh levels ofDNA
adducts appears to correlate positively with
favorable clinical outcome (118), and
therefore such analyses may become impor-
tant clinical dosimeters. In addition, they
serve to validate the assays commonly used
for human DNA adduct measurements,
since precise dosimetry is rarely possible in
a clinical setting.
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Correlation of DNA Adducts
with Other Biomarkers
The classes of biomarkers most likely to
correlate with PAH-DNA adduct mea-
surements are urinary metabolites (bio-
markers ofexposure), hemoglobin adducts
(surrogates for DNA adducts), mutagenesis
(biomarkers ofeffect), and polymorphisms
for enzymes involved in PAH metabolism
(biomarkers ofsusceptibility). Studies cur-
rently available in this area have been per-
formed with small numbers ofsubjects,
and conflicting correlations have some-
times been observed. However, as method-
ological advances improve the specificity of
biomarker analysis, there is the promise
that batteries ofsuch assays may be usefully
employed in future risk assessments.
Metabolic polymorphisms are consid-
ered to influence all the other classes of
biomarkers. The enzyme complex responsi-
ble for the initial metabolism ofPAHs, aryl
hydrocarbon hydroxylase (AHH), consists
of a battery ofenzymes that include cyto-
chrome P4501A1. The extent of AHH
activity in human lung microsomes has
been compared to DNA adduct levels
determined in the same lung samples by
either HPLC and fluorescence (specific for
BPdG) (119) or 32P-postlabeling (53).
Both DNA adduct detection methods
yielded results that correlated positively
with the extent ofAHH activity. Correla-
tions ofblood-cell DNA adduct levels with
CYPlAl have been examined in chimney
sweeps (155) and in California firefighters
(156) with ambivalent results. The lack of
agreement may be due to differences in
experimental approaches to determining
polymorphism and to detecting DNA
adducts, but it is also possible that neither
study had sufficient statistical power to
demonstrate subtle effects.
Another metabolic enzyme class, the
glutathione S-transferases (GSTs), is
involved in PAH detoxification. An 8-kb
deletion, including the entire coding
region of the GSTMI gene, renders the
null genotype in approximately 45% of
people who are homozygotes. This geno-
type has been implicated in increased
aflatoxin-DNA adduct formation. To
investigate PAH exposure levels in lung tis-
sue, Shields et al. (100) showed that mea-
surable BPdG adduct levels, by SFS and
IAC/32P-postlabeling, were present in six
of seven people with the null genotype.
Among individuals who were negative for
these adducts, only 12 of 31 individuals
had the null genotype. However, studies
with blood-cell DNA adduct measurements
did not show a similar correlation. For
example, PAH-DNA adduct levels, mea-
sured by ELISA in blood cells from heavily
smoking males with the null genotype
(32/63) were similar to those found in
matched individuals with homozygous or
heterozygous normal genotypes (31/63)
(120). In addition, in California fire-
fighters who had significant increases in
blood-cell PAH-DNA adducts due to
eating charbroiled food, the presence or
absence of the null genotype was not
associated with consistent fluctuations in
adduct levels (156). It is not likely that a
single metabolic polymorphism will be
the major determinant of cancer risk,
but the results from a metabolic profile
may be useful for future elucidation
ofsusceptibility.
Urinary metabolites, hemoglobin
adducts, and HPRTmutagenesis are being
analyzed in conjunction with DNA
adducts in human biomonitoring studies.
Although few ofthese multiple biomarker
studies are published, a number ofpromis-
ing new methodologies make this an
important direction for the future. Urinary
metabolites are considered to provide
direct evidence ofexposure and reflect the
activity of the enzymes discussed above.
The metabolite measured most frequently
is 1-OH-pyrene (121), and the extent and
timing of I-OH-pyrene excretion have
been correlated with occupational PAH
exposures (122). In one study, PAH-DNA
adducts and 1-OH-pyrene were measured
in Finnish Foundry workers at three levels
of ambient B[a]P exposure (41), and
whereas adducts did correlate with expo-
sure, the urinary metabolite did not.
Subsequently, analytical procedures have
been developed for the BP-7,10/8,9-tetrol
(123) and the 1-OH-pyrene glucuronide
(124), and these are now being measured
in conjunction with DNA adducts (106).
A number of methodological approaches
for PAH analysis ofhuman hemoglobin
have demonstrated the presence ofadducts
derived from B[a]P and chrysene
(66,125,126). Hemoglobin adducts of
B[a]P were measured concomitantly with
airborne PAH concentration in one study
(127), and a weak correlation was demon-
strated with exposure, but DNA adducts
were not measured. Attempts have been
made to correlate HPRTmutagenesis with
exposure and DNA adduct formation
in Finnish foundry workers (128,129).
There was a significant increase in HPRT
mutagenesis and DNA adduct formation
with exposure, but the numbers ofindivid-
uals in the mutagenesis portion of the
study were small (128) and the correlation
requires more substantial validation.
Taken together, these results demon-
strate that multiple biomarker correlations
are not necessarily straightforward. The tis-
sues studied, the nature of the parameters
being measured, and the capabilities ofthe
assays used should all be carefully scruti-
nized. The numbers ofsubjects available
may be insufficient for solid statistics, and
the validity ofa particular correlation may
not be established until after several inde-
pendent investigations are performed.
However, the present status of develop-
ment of several biomarkers suggests that
good correlation studies with PAH-DNA
adduct measurements can nowbe designed.
Conclusion
Human DNA adduct formation is a
promising biomarker for molecular cancer
epidemiology. The recent development of
methodologies capable ofmeasuring classes
ofadducts and specific adducts in human
blood and tissue samples is likely to lead to
improved risk assessment for groups of
exposed individuals and may indicate
opportunities for chemoprevention. This is
true not only for cancer but for other toxic
biological end points. Human DNA
adduct measurements have been most
widely used for exposure documentation.
The studies presented here demonstrate
that high ambient levels of B[a]P are asso-
ciated with high levels of DNA adducts in
human blood cell DNA and that DNA
adduct levels drop when the ambient PAH
levels decrease significantly. Precise human
DNA adduct dosimetry has been difficult
to achieve with PAHs because ofthe com-
plex nature ofthe exposures involved; how-
ever, correlating DNA adducts with other
exposure biomarkers such as urinary
metabolites and hemoglobin adducts may
substantiate ambient B[a]P measurements
and approach dosimetry. Correlations with
human mutagenesis and metabolic poly-
morphisms also suggest the importance of
a battery ofbiomarkers in elucidating toxic
mechanisms. It is likely that some toxic,
noncarcinogenic compounds may have
genotoxic effects and that adverse health
outcomes other than cancer may be corre-
lated with DNA adduct formation.
Therefore, the studies presented here may
serve as useful prototypes for exploration of
other toxic end points.
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